TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Photocure ASA ( (PHCUF) ) has issued an update.
Photocure ASA has released its Annual Report and integrated ESG report for 2024, approved by its Board of Directors. This announcement underscores the company’s commitment to transparency and accountability, potentially strengthening its position in the healthcare sector and reassuring stakeholders of its financial health and sustainability efforts.
More about Photocure ASA
Photocure ASA, known as The Bladder Cancer Company, is a leader in providing innovative solutions for bladder cancer treatment. Their unique technology enhances cancer cell visibility, improving patient outcomes globally. Based in Oslo, Norway, Photocure is publicly traded on the Oslo Stock Exchange.
YTD Price Performance: -18.80%
Average Trading Volume: 953
Technical Sentiment Signal: Strong Buy
Current Market Cap: $122.1M
For detailed information about PHCUF stock, go to TipRanks’ Stock Analysis page.